OTC

Through independent research and development, cooperative development, licensed introduction, and deep incubation, the company focuses on core treatment fields such as immunity, cardiovascular and cerebrovascular diseases, chronic diseases, and focuses on strengthening core technology platforms such as small molecules, cell therapy, and RNA, creating an open and global innovative research and development system, and actively exploring the layout of RNA, AI-assisted therapy and other technologies. Continue to enhance the core research and development capabilities and pipeline value, in order to promote the development and commercialization of more similar initiatives and similar quality products.